Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Myelin Oligodendrocyte Glycoprotein (MOG) Antibody-associated Disease (MOG-AD) [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating Rozanolixizumab for efficacy and safety in adults with MOG antibody-associated disease is actively not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease

Drugs mentioned

• Rozanolixizumab

Snippet

Sponsor: UCB Biopharma SRL | Conditions: Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOG-AD) | Phase 3 | Status: ACTIVE_NOT_RECRUITING